A fair comparison starts with the question
Same search result, very different research. Here's how I sort it out.
First, check what is being compared
MOTS-c, retatrutide and semaglutide often get grouped as metabolic peptides. Metabolic just means relating to how the body handles energy and materials. It's a big umbrella, with room for very different claims.
A mouse running farther, a person losing weight and a trial counting heart and stroke events are different kinds of evidence. None is a substitute for the others. Before looking for a winner, I look for the question each study asked.
| Peptide | What was studied? | What does that leave open? |
|---|---|---|
| Semaglutide | Human weight and heart-health trials. | Who benefits, which product and which approved use. |
| Retatrutide | Human weight trial with a liver-fat substudy. | Longer-term safety; no approved prescription product. |
| MOTS-c | Treatment experiments in cells and animals. | No published human treatment results; human risks unknown. |
Then, look at what changed
Semaglutide's STEP 1 trial found more average weight loss than placebo, a dummy treatment. Participants had obesity, or overweight plus a weight-related condition, and no diabetes. Its SELECT heart-health trial counted a combined outcome: cardiovascular death, nonfatal heart attack or nonfatal stroke. Participants were 45 or older, had cardiovascular disease and a BMI of at least 27, and had no diabetes. BMI relates weight to height. That second result gives a different kind of information.
Retatrutide's liver-fat substudy within its weight trial used MRI scans. Participants had obesity or overweight, excess liver fat and no type 2 diabetes. The substudy didn't establish fewer cases of liver failure. A scan can answer its own question without answering every question about future health.
The practical habit is simple: name what changed before deciding what it means. 'Health improved' can hide a lot. A measured change in one thing doesn't prove a benefit in another.
Keep mice and people in their own sentences
The MOTS-c performance experiments treated mice. The human part of that research measured the body's own peptide after exercise. Measuring a natural signal doesn't test the benefit of giving someone extra.
No human treatment studies of MOTS-c have been published. Its risks in people are unknown too. Neither gap disappears because a mechanism sounds convincing.
Separate human trials also need care when put side by side. Different participants, follow-up periods and comparison treatments can change the picture. A table of weight-loss percentages can look tidy while making an unfair comparison.
Finally, check the care question
Semaglutide has FDA-approved products with specific uses. Retatrutide remains investigational, with no approved prescription product. MOTS-c has no FDA-approved medicine.
Compounded medicines aren't FDA-approved either. FDA explains what that means for safety, effectiveness and quality. A clinician reviewing a request and FDA reviewing a product are different processes.
For your own reading, pick the question that brought you here: semaglutide, retatrutide or MOTS-c. Each page keeps the findings and gaps together. There's no need to make a treatment choice just to understand the difference.